Last reviewed · How we verify
Capecitabine and aflibercept — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Capecitabine and aflibercept (Capecitabine and aflibercept) — John Strickler, M.D..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Capecitabine and aflibercept TARGET | Capecitabine and aflibercept | John Strickler, M.D. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Capecitabine and aflibercept CI watch — RSS
- Capecitabine and aflibercept CI watch — Atom
- Capecitabine and aflibercept CI watch — JSON
- Capecitabine and aflibercept alone — RSS
Cite this brief
Drug Landscape (2026). Capecitabine and aflibercept — Competitive Intelligence Brief. https://druglandscape.com/ci/capecitabine-and-aflibercept. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab